Recent Investment Analysts’ Ratings Updates for Pharvaris (PHVS)

A number of firms have modified their ratings and price targets on shares of Pharvaris (NASDAQ: PHVS) recently:

• 7/18/2026 – Pharvaris was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Pharvaris had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Pharvaris is now covered by Wells Fargo & Company. They set an “overweight” rating and a $55.00 price target on the stock.
• 7/15/2026 – Pharvaris was upgraded by Wells Fargo & Company to “strong-buy”.
• 6/25/2026 – Pharvaris had its price target raised by Morgan Stanley from $41.00 to $46.00. They now have an “overweight” rating on the stock.
• 6/16/2026 – Pharvaris had its “buy” rating reaffirmed by HC Wainwright.
• 6/6/2026 – Pharvaris was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Transactions at Pharvaris

In other news, Director Elisabeth Bjork sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the sale, the director owned 15,167 shares in the company, valued at $444,696.44. This represents a 39.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Wim Souverijns sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.92, for a total transaction of $299,200.00. Following the sale, the insider directly owned 45,111 shares of the company’s stock, valued at $1,349,721.12. This trade represents a 18.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 178,322 shares of company stock worth $5,969,286 over the last quarter.

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.